The Global Market for HIV/AIDS Testing is Projected to Reach 1.2 Billion Tests, Worth US$5.9 Billion by 2020

Demand for Efficient & Technologically Advanced Tests for Unmet Needs of HIV Diagnosis Drives the HIV/AIDS Testing Market, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global HIV/AIDS Testing market. The global market for HIV/AIDS testing is projected to reach 1.2 billion tests, worth US$5.9 billion by 2020, driven by technological developments in rapid point-of-care HIV testing, and the yet huge unmet needs in accurate HIV diagnosis.

Acquired Immunodeficiency Syndrome (AIDS), caused by the human immunodeficiency virus (HIV), is recognized as the leading infectious killer disease globally. With substantial developments in testing and diagnosis, and initiation of Anti-Retroviral Therapy (ART), the disease is now deemed a chronic condition that requires early diagnosis and steady monitoring for enhanced life expectancy. The market for HIV/AIDS testing is witnessing steady growth, owing to the increasing number of people affected with HIV globally that are unaware of their infection status, and technological advancements resulting in the development of point-of-care, rapid tests, that can be employed in decentralized, remote settings.

The reasons for the increase in the number of HIV-infected people include lifestyle changes, rampant unprotected sex, injection drug usage, and lack of awareness about the mode of transmission and personal HIV status. A crucial factor driving market growth for testing is governmental and NGO efforts initiated against AIDS to reduce disease incidence and prolong life expectancy through expanded R&D efforts. Several MNCs have also adopted AIDS education programs to mitigate adverse impacts of the condition on their business and workplace. In addition, the high unmet HIV diagnostic/screening needs in African and Asian regions provide future growth opportunities for the testing market.

The global HIV-AIDS testing market is characterized by an increasing number of companies involved in research and development of new products. Product pipelines of leading players include several advanced point-of-care tests, among other innovations. The increase in the range of innovative diagnostics is expected to fuel market growth significantly. While screening tests, comprising ELISA and Rapid tests, constitute the largest test markets, monitoring tests (especially CD4+ cell count tests and viral load tests) that monitor the effectiveness of ART, represent the fastest growing test markets. Confirmatory tests include assays such as the Western Blot, Indirect Fluorescent Antibody assay (IFA), or the Radio Immuno Precipitation assay (RIPA). Prominent screening tests include point-of-care rapid blood tests and laboratory-based blood and urine tests. Competition in the market has intensified with the launch of rapid, advanced oral fluid tests. CLIA (Clinical Laboratory Improvement Amendments of 1988)-waived status of some newer tests allow their use outside clinical laboratories, in remote locations with no access to healthcare resources. FDA-approved home testing HIV kits available over the counter, are also expected to become increasingly popular, due to their adoption by more number of HIV-affected people who shun regular clinic visits. Though HIV testing is the basis of prevention and treatment of AIDS in several underdeveloped nations, paucity of funds and the need for state-of-the-art equipment to run standard tests hampers widespread adoption of HIV tests.

As stated by the new market research report on HIV/AIDS Testing, the United States represents the largest market in terms of value, supported by optimum government funding for R&D in HIV/AIDS testing, and favorable reimbursement policies. In terms of volume or the number of tests, a large percentage of people affected with HIV and AIDS in the African continent contributes to the high number of tests performed in the region. Asia-Pacific ranks as the fastest growing market with projected CAGR of 12.5% over the analysis period, led by thriving R&D for HIV diagnostics and partnerships among Western market players to penetrate this regional market.

Major players covered in the report include Abbott Laboratories Inc., Abbott Molecular Inc., Adaltis S.r.l., Alere, Beckman Coulter Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Calypte Biomedical Corporation, Chembio Diagnostic Systems Inc., Hologic Inc., Fujirebio Europe N.V., MedMira Inc., OraSure Technologies Inc., Ortho-Clinical Diagnostics Inc., Quest Diagnostics Inc., Roche Diagnostics, Siemens Healthcare Diagnostics Inc.,  and Trinity Biotech Plc., among others.

The research report titled “HIV/AIDS Testing: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the market trends, market issues, growth drivers, and strategic industry activity of global companies.  The report provides market estimates and projections for major geographic markets, including the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, and Rest of Europe), Asia-Pacific, Latin America, and Rest of World. Test types analyzed include HIV/AIDS Screening Tests and HIV/AIDS Confirmatory Tests in terms of volume. In value terms, test types analyzed include

HIV/AIDS Screening Tests, HIV/AIDS Confirmatory Tests, and HIV/AIDS Monitoring Tests.

Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.